MabVax Therapeutics, Inc. Employee Directory

Biotechnology ResearchCalifornia, United States2-10 Employees

MabVax Therapeutics is a clinical-stage biotechnology company based in San Diego, California, focused on translating antibody-based cancer therapies into human studies. It operates a fully human antibody discovery platform aimed at accelerating the development of treatments for unmet cancer-related needs. The lead candidate, MVT-5873, is a fully human IgG1 monoclonal antibody directed at sialyl Lewis A on CA19-9 and is evaluating in Phase 1 trials for pancreatic cancer and other CA19-9–positive tumors. The company collaborates with institutions such as Memorial Sloan Kettering Cancer Center and Rockefeller University, and has treated about 50 patients in Phase 1 studies with MVT-5873 or the PET imaging product MVT-2163. 
 In addition to MVT-5873, MabVax is progressing a radioimmunotherapy candidate, MVT-1075, with patient dosing already underway in a Phase 1 study. The organization also has an imaging-focused product, MVT-2163, developed for diagnostic purposes and studied alongside therapeutic efforts in early clinical testing.

Sign up for free to view info

Company overview Email format